可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Johansson BL,Souza DSR,Bodin L,et al.No touch vein harvesting technique for CABG improves the long-term clinical outcome[J].Scand Cardiovasc J,2009,43(1):63-68.[2]Chan V,Kulik A,Bourke ME,et al.Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery[J].J Card Surg,2007,22(6):493-497.[3]Zou RJ,Zou LJ,Huang SD,et al.Effect of external stents on prevention of intimal hyperplasia in a canine vein graft model[J].Chin Med J (Engl),2007,120(24):2264-2267.[4]Haraguchi T,Okada K,Tabata Y,et al.Controlled release of basic fibroblast growth factor from gelatin hydrogel sheet improves structural and physiological properties of vein graft in rat[J].Arterioscler Thromb Vasc Biol,2007,27(3):548-555.[5]de Graaf R,Kloppenburg G,Tintu A,et al.The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model[J].Vascul Pharmacol,2009,50(3-4):83-88.[6]Cayci C,Wahlquist TC,Seckin SI,et al.Naringenin inhibits neointimal hyperplasia following arterial reconstruction with interpositional vein graft[J].Ann Plast Surg,2010,64(1):105-113.[7]Schwalm JD,Ahmad M,Velianou JL,et al.Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience[J].Can J Cardiol,2010, 26(2):e40-e44.[8]Simsek C,Onuma Y,Magro M,et al.Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease[J].Catheter Cardiovasc Interv,2010,76(1):41-49.[9]Simsek C,Magro M,Boersma E,et al.The unrestricted use of sirolimus-and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries[J].JACC Cardiovasc Interv,2010,3(10):1051-1058.[10]Vink MA,Dirksen MT,Suttorp MJ,et al.5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction:a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial[J].JACC Cardiovasc Interv,2011,4(1):24-29.[11]Fujita H,Banno H,Yamanouchi D,et al.Pitavastatin Inhibits Intimal Hyperplasia in Rabbit Vein Graft[J].J Surg Res,2008,148(2):238-243.[12]Rodés-Cabau J,Bertrand OF,Larose E,et al.Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial[J].Circulation,2009,120(20):1978-1986.[13]Brilakis ES,Lichtenwalter C,Abdel-Karim AR,et al.Continued Benefit From Paclitaxel-Eluting Compared With Bare-Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting of Saphenous Vein Grafts) Trial[J].JACC Cardiovasc Interv,2011,4(2):176-182.[14]Wijns W,Kolh P,Danchin N,et al.Guidelines on myocardial revascularization[J].Eur Heart J,2010,31(20):2501-2555.